vs
CAMDEN NATIONAL CORP（CAC）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是CAMDEN NATIONAL CORP的1.1倍（$69.8M vs $64.3M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 34.0%，领先350.0%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 22.6%）
卡姆登国民银行是一家总部位于美国缅因州卡姆登的商业银行，是上市银行控股公司卡姆登国民集团的核心子公司。该行创立于1875年，1984年完成企业重组后成为控股公司直接持有的全资子公司。2025年与诺斯韦金融合并后，合并后机构总资产约为70亿美元。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CAC vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.1倍
$64.3M
净利率更高
RIGL
高出350.0%
34.0%
两年增速更快
RIGL
近两年复合增速
22.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.3M | $69.8M |
| 净利润 | $21.9M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 34.0% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $1.29 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACRIGL
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $69.8M | ||
| Q3 25 | $65.4M | $69.5M | ||
| Q2 25 | $62.3M | $101.7M | ||
| Q1 25 | $60.1M | $53.3M | ||
| Q4 24 | $47.6M | $57.6M | ||
| Q3 24 | $45.0M | $55.3M | ||
| Q2 24 | $42.8M | $36.8M |
净利润CACRIGL
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | $268.1M | ||
| Q3 25 | $21.2M | $27.9M | ||
| Q2 25 | $14.1M | $59.6M | ||
| Q1 25 | $7.3M | $11.4M | ||
| Q4 24 | $14.7M | $14.3M | ||
| Q3 24 | $13.1M | $12.4M | ||
| Q2 24 | $12.0M | $-1.0M |
毛利率CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | 33.2% | ||
| Q3 25 | 40.5% | 40.9% | ||
| Q2 25 | 28.5% | 60.1% | ||
| Q1 25 | 10.3% | 23.9% | ||
| Q4 24 | 38.7% | 28.9% | ||
| Q3 24 | 35.2% | 25.4% | ||
| Q2 24 | 34.7% | 1.2% |
净利率CACRIGL
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | 384.0% | ||
| Q3 25 | 32.4% | 40.2% | ||
| Q2 25 | 22.6% | 58.6% | ||
| Q1 25 | 12.2% | 21.5% | ||
| Q4 24 | 30.8% | 24.9% | ||
| Q3 24 | 29.1% | 22.5% | ||
| Q2 24 | 28.0% | -2.8% |
每股收益（稀释后）CACRIGL
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $14.11 | ||
| Q3 25 | $1.25 | $1.46 | ||
| Q2 25 | $0.83 | $3.28 | ||
| Q1 25 | $0.43 | $0.63 | ||
| Q4 24 | $1.00 | $0.82 | ||
| Q3 24 | $0.90 | $0.70 | ||
| Q2 24 | $0.81 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $155.0M |
| 总债务越低越好 | $514.4M | $52.5M |
| 股东权益账面价值 | $710.0M | $391.5M |
| 总资产 | $7.0B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.72× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M |
总债务CACRIGL
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益CACRIGL
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $391.5M | ||
| Q3 25 | $676.4M | $117.6M | ||
| Q2 25 | $652.1M | $81.9M | ||
| Q1 25 | $640.1M | $18.6M | ||
| Q4 24 | $531.2M | $3.3M | ||
| Q3 24 | $529.9M | $-14.6M | ||
| Q2 24 | $508.3M | $-29.9M |
总资产CACRIGL
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $513.6M | ||
| Q3 25 | $7.0B | $242.5M | ||
| Q2 25 | $6.9B | $206.7M | ||
| Q1 25 | $7.0B | $176.0M | ||
| Q4 24 | $5.8B | $164.0M | ||
| Q3 24 | $5.7B | $139.4M | ||
| Q2 24 | $5.7B | $128.4M |
负债/权益比CACRIGL
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $22.0M | ||
| Q3 25 | $36.1M | $24.0M | ||
| Q2 25 | $6.0M | $30.5M | ||
| Q1 25 | $1.0M | $-893.0K | ||
| Q4 24 | $60.9M | $14.5M | ||
| Q3 24 | $-14.5M | $21.7M | ||
| Q2 24 | $14.5M | $302.0K |
自由现金流CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | — | ||
| Q3 25 | $35.4M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-727.0K | — | ||
| Q4 24 | $55.4M | — | ||
| Q3 24 | $-16.2M | — | ||
| Q2 24 | $13.2M | — |
自由现金流率CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | — | ||
| Q3 25 | 54.1% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | -1.2% | — | ||
| Q4 24 | 116.4% | — | ||
| Q3 24 | -36.0% | — | ||
| Q2 24 | 30.8% | — |
资本支出强度CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.0% | — |
现金转化率CACRIGL
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | 0.08× | ||
| Q3 25 | 1.70× | 0.86× | ||
| Q2 25 | 0.43× | 0.51× | ||
| Q1 25 | 0.14× | -0.08× | ||
| Q4 24 | 4.15× | 1.01× | ||
| Q3 24 | -1.11× | 1.75× | ||
| Q2 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
RIGL
暂无分部数据
